Study ID: CTSU C90601

Randomized Double-Blind Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma


The purpose of this study is to compare the effects of the combination of the chemotherapy drugs gemcitabine and cisplatin with the combination of gemcitabine, cisplatin, and the experimental drug bevacizumab on patients and patient¿s transitional cell cancer to find out which is better.Participants in this study have been diagnosed with advanced transitional cell cancer of the urinary tract (Advanced Transitional Cell Carcinoma). Bevacizumab is an antibody that works by blocking a protein called VEGF and inhibiting growth of new blood vessels. The combination of gemcitabine and cisplatin is one commonly used treatment that has been shown to make some patients with transitional cell carcinoma live longer. This research is being done to see if adding bevacizumab to gemcitabine and cisplatin will delay the growth of this cancer and allow patients to live longer.

Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Phase III


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list